Revvity Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.89. The key difference: Revvity Inc pays a 0.22% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Revvity Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| RVTY | USIG | |
|---|---|---|
Market Cap | $14.18B | — |
Sector | Technology | Fixed Income |
52-Week High | $130.94 | $52.69 |
52-Week Low | $82.26 | $49.89 |
Enterprise Value | $16.50B | — |
Dividend Yield | 0.22% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
USIG trades at $49.96, down 0.08% on the day, with technical indicators showing a bearish trend. Recent corporate actions include scheduled dividend payments in 2026. Institutional interest is evident from new stakes by Blue Edge Capital LLC and increased holdings by Bank of New York Mellon Corp, as reported by Defense World and Business Wire in July and August 2026.
The outlook remains cautious due to bearish technical signals and lack of recent fundamental data. Investment opportunities hinge on future financial disclosures and institutional support, while risks include market volatility and reliance on upcoming earnings for valuation clarity.
Trailing returns across standard periods
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →